Trial reportAnnals of internal medicine2013
Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.
Trial report in Annals of internal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 127 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study
Who cites it
127 citing papers in PubMed, 5 syntheses or guidelines pooled it, 248 citations in OpenAlex.
- The effect of aspirin on inflammatory response in intracranial aneurysm: a systematic review.Inflammopharmacology · 2025Pooled it
- Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review.Diabetologia · 2024Pooled it
- Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus.Frontiers in immunology · 2023Pooled it
- Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability.Nature communications · 2021Pooled it
- Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients.Seminars in immunopathology · 2019Pooled it
- A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss.Nature metabolism · 2025Trial
- Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial.Diabetes, obesity & metabolism · 2017Trial
- C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Trial
- Renal Toxicity Associated with Salsalate in Elderly Adults with Anemia.Journal of the American Geriatrics Society · 2016Trial
- Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics.Obesity (Silver Spring, Md.) · 2015Trial
- The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.Diabetes care · 2014Trial
- The effect of salsalate therapy on endothelial function in a broad range of subjects.Journal of the American Heart Association · 2014Trial
- Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).Diabetes care · 2013Trial
- Salsalate-induced changes in lipid, lipoprotein, and apoprotein concentrations in overweight or obese, insulin-resistant, nondiabetic individuals.Journal of clinical lipidologyTrial
- Interleukin-19 Regulates Adipose Tissue Dysfunction in Obesity: Interplay Between Inflammation and Vascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Atypical involvement of Alzheimer's tau proteins in diseases beyond tauopathies.Life medicine · 2026Review
- Orphan GPCRs in diabetes mellitus: metabolic control, inflammation, and drug development.Frontiers in endocrinology · 2026Review
- Hypothalamic Prostaglandins Facilitate Recovery From Severe Hypoglycemia but Exacerbate Recurrent Hypoglycemia in Mice.Diabetes · 2025Article
- A narrative review of epicardial adipose tissue as a predictor of cardiometabolic risk in rheumatoid arthritis patients.Annals of translational medicine · 2025Review
- Salsalate improves the anti-tumor efficacy of lenvatinib in MASH-driven hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2025Article
67 more citing papers are in PubMed but not listed here.
Corrections and comments
- SummaryForPatientsIn
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundShort-duration studies show that salsalate improves glycemia in type 2 diabetes mellitus (T2DM).
objectiveTo assess 1-year efficacy and safety of salsalate in T2DM.
designPlacebo-controlled, parallel trial; computerized randomization and centralized allocation, with patients, providers, and researchers blinded to assignment. (ClinicalTrials.gov: NCT00799643).
setting3 private practices and 18 academic centers in the United States. PATIENTS: Persons aged 18 to 75 years with fasting glucose levels of 12.5 mmol/L or less (≤225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% who were treated for diabetes.
intervention286 participants were randomly assigned (between January 2009 and July 2011) to 48 weeks of placebo (n = 140) or salsalate, 3.5 g/d (n = 146), in addition to current therapies, and 283 participants were analyzed (placebo, n = 137; salsalate, n = 146). MEASUREMENTS: Change in hemoglobin A1c level (primary outcome) and safety and efficacy measures.
resultsThe mean HbA1c level over 48 weeks was 0.37% lower in the salsalate group than in the placebo group (95% CI, -0.53% to -0.21%; P < 0.001). Glycemia improved despite more reductions in concomitant diabetes medications in salsalate recipients than in placebo recipients. Lower circulating leukocyte, neutrophil, and lymphocyte counts show the anti-inflammatory effects of salsalate. Adiponectin and hematocrit levels increased more and fasting glucose, uric acid, and triglyceride levels decreased with salsalate, but weight and low-density lipoprotein cholesterol levels also increased. Urinary albumin levels increased but reversed on discontinuation; estimated glomerular filtration rates were unchanged. LIMITATION: Trial duration and number of patients studied were insufficient to determine long-term risk-benefit of salsalate in T2DM.
conclusionSalsalate improves glycemia in patients with T2DM and decreases inflammatory mediators. Continued evaluation of mixed cardiorenal signals is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.